Resistance to Targeted Anti-Cancer Therapeutics
Resistance to Anti-Cancer Therapeutics Targeting Receptor Tyrosine Kinases and Downstream Pathways
Yosef Yarden | Moshe Elkabets
Medical / Oncology / General
Comprehensively covers the multiplicity and diversity of mechanisms underlying resistance to the currently approved drugs, both tyrosine kinase inhibitors and monoclonal antibodies, that specifically inhibit growth factor receptors playing driver or survival functions in cancer
Examines specific targets and the cognate drugs
Evaluates molecular modes of innate and evolving resistance
Yosef Yarden, PhD, is Professor, Department of Biological Regulation, The Weizmann Institute of Science, Israel.
| Publication Date: |
10 April 2018 |
| Publisher: |
Springer International Publishing |
| Imprint: |
Springer |
| ISBN-13: |
9783319679303 |
| Format: |
Hardback |
| Page Count: |
242 |